COMPETITIVE COMPOSITIONS OF NUCLEIC ACID MOLECULES FOR ENRICHMENT OF RARE-ALLELE-BEARING SPECIES
20210371911 · 2021-12-02
Assignee
Inventors
Cpc classification
C12Q2525/186
CHEMISTRY; METALLURGY
C12Q2525/161
CHEMISTRY; METALLURGY
C12Q2525/186
CHEMISTRY; METALLURGY
C12Q2563/131
CHEMISTRY; METALLURGY
C12Q2563/131
CHEMISTRY; METALLURGY
C12Q1/6806
CHEMISTRY; METALLURGY
C12Q1/6806
CHEMISTRY; METALLURGY
International classification
Abstract
The present disclosure describes the thermodynamic design and concentrations necessary to design probe compositions with desired optimal specificity that enable enrichment, detection, quantitation, purification, imaging, and amplification of rare-allele-bearing species of nucleic acids (prevalence <1%) in a large stoichiometric excess of a dominant-allele-bearing species (wildtype). Being an enzyme-free and homogeneous nucleic acid enrichment composition, this technology is broadly compatible with nearly all nucleic acid-based biotechnology, including plate reader and fluorimeter readout of nucleic acids, microarrays, PCR and other enzymatic amplification reactions, fluorescence barcoding, nanoparticle-based purification and quantitation, and in situ hybridization imaging technologies.
Claims
1. A nucleic acid detection composition comprising: a target nucleic acid probe comprising a first target probe oligonucleotide and a second target probe oligonucleotide, wherein the first target probe oligonucleotide comprises a target probe complement region that is complementary to a target nucleic acid sequence, wherein the second target probe oligonucleotide comprises a target probe protector region that is complementary to a first target probe complement subsequence of the target probe complement region thereby providing a target double-stranded probe portion and a target single-stranded probe portion, wherein the target double-stranded probe portion comprises the first target probe complement subsequence and the target probe protector region, and the target single-stranded probe portion comprises a second target probe complement subsequence of the target probe complement region; a target auxiliary oligonucleotide, wherein the target auxiliary oligonucleotide is the second target probe oligonucleotide separate from the target nucleic acid probe; a variant nucleic acid probe comprising a first variant probe oligonucleotide and a second variant probe oligonucleotide, wherein the first variant probe oligonucleotide comprises a variant probe complement region that is complementary to a variant nucleic acid sequence, wherein the second variant probe oligonucleotide comprises a variant probe protector region that is complementary to a first variant probe complement subsequence of the variant probe complement region thereby providing a variant double-stranded probe portion and a variant single-stranded probe portion, wherein the variant double-stranded probe portion comprises the first variant probe complement subsequence and the variant probe protector region, and the variant single-stranded probe portion comprises a second variant probe complement subsequence of the variant probe complement region, wherein the target probe complement region and the variant probe complement region share at least two conserved sequences separated by a non-conserved sequence; and a variant auxiliary oligonucleotide, wherein the variant auxiliary oligonucleotide is the second variant oligonucleotide separate from the variant nucleic acid probe.
2. The composition of claim 1 wherein the non-conserved sequence is a single nucleotide.
3. The composition of claim 1 wherein the target probe complement region and the variant probe complement region share two conserved sequences separated by a non-conserved sequence.
4. The composition of claim 3 wherein the non-conserved sequence is a single nucleotide.
5. The composition of claim 1 wherein the first target probe oligonucleotide comprises a detectable label or a capture moiety conjugated thereto.
6. The composition of claim 5 wherein the second target probe oligonucleotide comprises a quencher sufficient to prevent detection of the detectable label or capture of the capture moiety.
7. The composition of claim 1 further comprising a third target probe oligonucleotide hybridized to a target probe non-complement region of the first target probe oligonucleotide, wherein the third target probe oligonucleotide comprises a detectable label or a capture moiety conjugated thereto, and a fourth target probe oligonucleotide hybridized to a target probe non-protector region of the second target probe oligonucleotide, wherein the fourth target probe oligonucleotide comprises a quencher sufficient to prevent detection of the detectable label or capture of the capture moiety.
8. The composition of claim 1 wherein the concentration of the variant nucleic acid probe relative to the concentration of the target nucleic acid probe is from greater than 1:1 to about less than 100000:1.
9. The composition of claim 1 wherein the concentration of the target auxiliary oligonucleotide relative to the concentration of the target nucleic acid probe is from greater than 1:1000 to less than 100000:1.
10. The composition of claim 1 wherein the concentration of the variant auxiliary oligonucleotide relative to the concentration of the variant nucleic acid probe is from greater than 1:1000 to less than 100000:1.
11. The composition of claim 1 wherein the target nucleic acid probe has a target reaction standard free energy (ΔG°.sub.rxn1), wherein the variant nucleic acid probe has a variant reaction standard free energy (ΔG°.sub.rxn2), and wherein ΔG°.sub.rxn1 is greater than the sum of ΔG°.sub.rxn2+1 kcal/mol.
12. The composition of claim 1 wherein the target nucleic acid probe has a concentration-adjusted target reaction standard free energy defined as ΔG°.sub.rxn1+Rτ ln([P.sub.t]/[P.sub.tC.sub.t]), wherein the variant nucleic acid probe has a variant reaction standard free energy defined as ΔG°.sub.rxn2+Rτ ln([P.sub.v]/[P.sub.vC.sub.v]), where R is the ideal gas constant, τ is the temperature in Kelvin, P.sub.t is the initial concentration of the target auxiliary oligonucleotide, P.sub.tC.sub.t is the initial concentration of the target nucleic acid probe, P.sub.v is the initial concentration of the variant auxiliary oligonucleotide, P.sub.vC.sub.v is the initial concentration of the variant nucleic acid probe, wherein the concentration-adjusted reaction standard free energy of the target nucleic acid probe is greater than the sum of the concentration-adjusted reaction standard free energy of the variant nucleic acid probe +1 kcal/mol.
13. The composition of claim 1 wherein the target nucleic acid probe has a target reaction standard free energy (ΔG°.sub.rxn1), wherein the variant nucleic acid probe has a variant reaction standard free energy (ΔG°.sub.rxn2), and wherein ΔG°.sub.rxn1 is greater than ΔG°.sub.rxn2, and ΔG°.sub.rxn2 is greater than −7 kcal/mol.
14. The composition of claim 1 wherein the target nucleic acid probe further comprises a third oligonucleotide and a fourth oligonucleotide, wherein the third oligonucleotide comprises a first target probe oligonucleotide-specific subsequence and a fourth oligonucleotide specific subsequence, wherein the first target probe oligonucleotide-specific subsequence is complementary to a target probe non-complement region of the first target probe oligonucleotide, wherein the fourth oligonucleotide comprises a second target probe oligonucleotide-specific subsequence and a third oligonucleotide-specific subsequence, wherein the second target probe oligonucleotide-specific subsequence is complementary to a target probe non-protector region of the second target probe oligonucleotide, wherein the target probe non-protector region of the second target probe oligonucleotide does not overlap with the target probe protector region, wherein the fourth oligonucleotide-specific subsequence is complementary to the third oligonucleotide-specific subsequence, and wherein the target auxiliary oligonucleotide further comprises the fourth oligonucleotide.
15. The composition of claim 14 wherein the fourth oligonucleotide-specific subsequence of the third oligonucleotide comprises a detectable label or a capture moiety conjugated thereto, and wherein the third oligonucleotide-specific subsequence of the fourth oligonucleotide comprises a quencher sufficient to prevent detection of the detectable label or capture of the capture moiety.
16. The composition of claim 1 wherein the variant nucleic acid probe further comprises a third oligonucleotide and a fourth oligonucleotide, wherein the third oligonucleotide comprises a first variant probe oligonucleotide-specific subsequence and a fourth oligonucleotide specific subsequence, wherein the first variant probe oligonucleotide-specific subsequence is complementary to a variant probe non-complement region of the first variant probe oligonucleotide, wherein the fourth oligonucleotide comprises a second variant probe oligonucleotide-specific subsequence and a third oligonucleotide-specific subsequence, wherein the second variant probe oligonucleotide-specific subsequence is complementary to a variant probe non-protector region of the second variant probe oligonucleotide, wherein the variant probe non-protector region of the second variant probe oligonucleotide does not overlap with the variant probe protector region, wherein the fourth oligonucleotide-specific subsequence is complementary to the third oligonucleotide-specific subsequence, and wherein the variant auxiliary oligonucleotide further comprises the fourth oligonucleotide.
17. A nucleic acid detection composition comprising: a target nucleic acid probe comprising a first target probe oligonucleotide and a second target probe oligonucleotide, wherein the first target probe oligonucleotide comprises a target probe complement region that is complementary to a target nucleic acid sequence, wherein the second target probe oligonucleotide comprises a target probe protector region that is complementary to a first target probe complement subsequence of the target probe complement region thereby providing a target double-stranded probe portion and a target single-stranded probe portion, wherein the target double-stranded probe portion comprises the first target probe complement subsequence and the target probe protector region, and the target single-stranded probe portion comprises a second target probe complement subsequence of the target probe complement region; a target auxiliary oligonucleotide, wherein the target auxiliary oligonucleotide is the second target probe oligonucleotide separate from the target nucleic acid probe; and a variant nucleic acid probe comprising a first variant probe oligonucleotide, wherein the first variant probe oligonucleotide comprises a variant probe complement region that is complementary to a variant nucleic acid sequence, wherein the target probe complement region and the variant probe complement region share at least two conserved sequences separated by a non-conserved sequence.
18. The composition of claim 17 wherein the target nucleic acid probe further comprises a third oligonucleotide and a fourth oligonucleotide, wherein the third oligonucleotide comprises a first target probe oligonucleotide-specific subsequence and a fourth oligonucleotide specific subsequence, wherein the first target probe oligonucleotide-specific subsequence is complementary to a target probe non-complement region of the first target probe oligonucleotide, wherein the fourth oligonucleotide comprises a second target probe oligonucleotide-specific subsequence and a third oligonucleotide-specific subsequence, wherein the second target probe oligonucleotide-specific subsequence is complementary to a target probe non-protector region of the second target probe oligonucleotide, wherein the target probe non-protector region of the second target probe oligonucleotide does not overlap with the target probe protector region, wherein the fourth oligonucleotide-specific subsequence is complementary to the third oligonucleotide-specific subsequence, and wherein the target auxiliary oligonucleotide further comprises the fourth oligonucleotide.
19. A nucleic acid detection composition comprising: a target nucleic acid probe comprising a first target probe oligonucleotide, wherein the first target probe oligonucleotide comprises a target probe complement region that is complementary to a target nucleic acid sequence; a variant nucleic acid probe comprising a first variant probe oligonucleotide and a second variant probe oligonucleotide, wherein the first variant probe oligonucleotide comprises a variant probe complement region that is complementary to a variant nucleic acid sequence, wherein the second variant probe oligonucleotide comprises a variant probe protector region that is complementary to a first variant probe complement subsequence of the variant probe complement region thereby providing a variant double-stranded probe portion and a variant single-stranded probe portion, wherein the variant double-stranded probe portion comprises the first variant probe complement subsequence and the variant probe protector region, and the variant single-stranded probe portion comprises a second variant probe complement subsequence of the variant probe complement region, wherein the target probe complement region and the variant probe complement region share at least two conserved sequences separated by a non-conserved sequence; and a variant auxiliary oligonucleotide, wherein the variant auxiliary oligonucleotide is the second variant oligonucleotide separate from the variant nucleic acid probe.
20. The composition of claim 19 wherein the variant nucleic acid probe further comprises a third oligonucleotide and a fourth oligonucleotide, wherein the third oligonucleotide comprises a first variant probe oligonucleotide-specific subsequence and a fourth oligonucleotide specific subsequence, wherein the first variant probe oligonucleotide-specific subsequence is complementary to a variant probe non-complement region of the first variant probe oligonucleotide, wherein the fourth oligonucleotide comprises a second variant probe oligonucleotide-specific subsequence and a third oligonucleotide-specific subsequence, wherein the second variant probe oligonucleotide-specific subsequence is complementary to a variant probe non-protector region of the second variant probe oligonucleotide, wherein the variant probe non-protector region of the second variant probe oligonucleotide does not overlap with the variant probe protector region, wherein the fourth oligonucleotide-specific subsequence is complementary to the third oligonucleotide-specific subsequence, and wherein the variant auxiliary oligonucleotide further comprises the fourth oligonucleotide.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
DESCRIPTION OF THE INVENTION
[0071] In the present disclosure, a novel reagent mixture composition (referred to herein as a “Competitive Composition) is provided. The Competitive Composition reacts with a heterogeneous sample mixture containing at last two closely related nucleic acid species: a dominant-allele-bearing species (Variant) and a rare-allele-bearing species (Target), with the former typically in excess of the latter (
[0072] The Competitive Composition comprises a target nucleic acid probe (Probe) and a variant nucleic acid probe (Sink), with the later in excess concentration of the former, with the Sink reacting more favorably with the Variant than with the Target (due to the Sink's complementarity to the dominant allele nucleotide(s)) and the Probe reacting more favorably with the Target than with the Variant (due to the Probe's complementarity to the rare allele nucleotide(s)).
[0073] Mathematically, the concentration ratio of Variant to Target ([Variant]/[Target]) in the initial sample is here denoted as X, and the concentration ratio of Variant to Target that is bound to the Probe after the reaction is denoted as Y. By using Competitive Compositions designed based on the guidelines described here, Y will be much smaller than X; our experimental data across 44 different cancer-related mutations shows an average enrichment ratio (X/Y) of around 1000.
[0074] This enrichment ratio for the present Competitive Composition is significantly higher than prior art regarding the use of a single probes alone. In addition to showing experimental results that compare favorably to prior art, the present disclosure additionally includes validated theoretical analysis and simulations explaining why the Competitive Compositions described here provide an advantage over strategies.
Components of Competitive Composition
[0075] There components of the Competitive Composition comprise a target nucleic acid probe (Probe), a variant nucleic acid probe (Sink), and a target auxiliary oligonucleotide and a target auxiliary oligonucleotide. Both the Probe and Sink can comprise single or double Blocks, where a Block is either a strand or a complex that comprises 2 or more oligonucleotides formed through Watson-Crick hybridization reactions. Single-Block Probe or Sink comprises Target-binding Block, while double-Block Probe or Sink further comprises an Auxiliary Block in addition to the Target-binding Block. The Auxiliary Block releases from the Target-binding Block concurrently with the hybridization of the Target or Variant. Each of these components is a nucleic acid molecule and can adopt any of a number of different morphologies (
[0076] Each of these designs generally possesses some degree of tunability in reaction favorability with their intended target (i.e. Target for Probe, Variant for Sink). For example, the standard free energy of hybridization (ΔG°.sub.rxn) can be modulated via the length of the single-stranded toehold regions for Yin-Yang probes, toehold probes, X-probes, and hairpin probes; the length of nonhomologous regions for toehold probes and X-probes. For single-stranded components (e.g. molecular beacons, hairpin probes, triple-stem probes), reaction favorability can be tuned via component concentration.
[0077] For purposes of illustrating one embodiment of the present disclosure, a particular exemplary Competitive Composition comprising an X-probe for the Probe and an toehold probe for the Sink will be described. It should be understood that this specific embodiment is to provide an example of the Competitive Composition, and is not meant to limit the Competitive Composition to this embodiment.
[0078] As shown in
[0079] As the X-probe is introduced into a sample containing target T and under the proper temperature and buffer conditions as shown in
[0080] Continuing with
[0081] Although not shown in
[0082] In another embodiment, the target nucleic acid probe of the competitive composition may comprise a toehold probe instead of a X-probe, and the non-target nucleic acid probe or Sink probe may comprise a toehold probe or an X-probe. In yet another embodiment, the target nucleic acid probe may comprise a toehold probe or an X probe and the non-target nucleic acid probe or Sink probe may comprise a single oligonucleotide. In yet another embodiment, the target nucleic acid probe may comprise a single oligonucleotide and the Sink probe may comprise either a toehold probe or a X-probe.
[0083] As explained in more detail below, based on its sequence, the target nucleic acid probe (Probe) has a target reaction standard free energy with the target nucleic acid sequence T defined as ΔG°.sub.rxn1, whereas the reaction of the Probe with the variant or non-target nucleic acid strand V will have a reaction standard free energy ΔG°.sub.rxn3 that will be weaker (more positive or less negative) than ΔG°.sub.rxn1 due to the mismatch base. Moreover, the Sink will act in the opposite fashion where its reaction standard free energy with the target (ΔG°.sub.rxn4) will be weaker that its reaction standard free energy with the variant (ΔG°.sub.rxn2) due to the mismatch base in the target T. Moreover, in certain embodiments, ΔG°.sub.rxn1 will be weaker (more positive or less negative) then ΔG°.sub.rxn2. More specifically, in certain embodiments, the relationship between ΔG°.sub.rxn1 and ΔG°.sub.rxn2 can be defined as, for example, ΔG°.sub.rxn1 is greater than the sum of ΔG°.sub.rxn2+1 kcal/mol, or alternatively ΔG°.sub.rxn1 is greater than ΔG°.sub.rxn2 where ΔG°.sub.rxn2 is greater than −7 kcal/mol. As used herein, the term “greater than” as used in connection with the standard reaction free energies of the Probe to target T and Sink to variant V means more positive or less negative (e.g. −4 kcal/mol is “greater than”−7 kcal/mol). Thus, in many instances, the composition of the present disclosure comprises a target nucleic acid probe that interacts with the target nucleic acid T less favorably than the non-target nucleic acid probe (Sink) interacts with the non-target nucleic acid variant V. In most samples in which the competitive compositions described above will be used, the non-target nucleic acid species or variant V is present on the dominant allele and will therefore be in excess of the target nucleic acid species T present on the rare allele.
[0084] In any of the above embodiments, any one of the strands of the probe may further comprise a synthetic nucleic acid analog such as LNA, PNA, 2′O-methyl substituted RNA, L-DNA, and speigelmers. In an alternative, any one of the strands of the probe may further comprise synthetic or natural analogs such as isosine, methylated nucleotides, iso-cytosine and iso-guanine, spiegelmer nucleotides, and xDNA.
[0085] The terms “polynucleotide,” “nucleic acid,” “oligonucleotide,” “nucleic acid species,” and “nucleic acid molecule” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. A polynucleotide may be further modified, such as by conjugation with a labeling component.
[0086] A process for preparing an X-probe is provided. In one embodiment, the third oligonucleotide (A), the fourth oligonucleotide (B), the second target (or non-target) oligonucleotide (P), and the first target (or non-target) oligonucleotide (C) are mixed together in aqueous solution. In one embodiment, the concentration of the first target (or non-target) oligonucleotide C is in excess of the third oligonucleotide A, the concentration of the second target (or non-target) oligonucleotide (P) is in excess of the first target (or non-target) oligonucleotide (C), and the concentration of the fourth oligonucleotide (B) is in excess of the protector strand such that a probe mixture is formed comprising complex BPCA, complex BPC, complex BP, and strand B. In another embodiment, the concentration of P is in excess of B, the concentration of C is in excess of P, and the concentration of A is in excess of C such that a probe mixture formed comprises complex BPCA, complex PCA, complex CA, and strand A.
[0087] In any of the above embodiments, the probe components are thermally annealed following mixing. In one embodiment, the thermal annealing includes heating the mixture to a temperature no less than 65° C., and cooling to a temperature no higher than 45° C. In another embodiment, the thermal annealing includes heating the mixture to a temperature no less than 80° C., and cooling to a temperature no higher than 60° C. In yet another embodiment, the thermal annealing includes heating the mixture to a temperature no less than 95° C., and cooling to a temperature no higher than 75° C.
[0088] In an alternative embodiment, the probe components are isothermally annealed through addition of salt or high salinity solutions. In yet another embodiment, the probe components are isothermally annealed through removal or dilution of formamide or other denaturants.
[0089] The probes of the present disclosure can be used in a variety of assays including, but not limited to the following: specific DNA or RNA detection or quantitation via fluorescence; specific DNA or RNA imaging via fluorescence; specific DNA or RNA detection, quantitation, or imaging via chromagenic methods (e.g. haptenated probes, and subsequent antibody-based recruitment of horseradish peroxidase (HRP) or alkaline phosphate (AP).
Competitive Composition Reactions
[0090]
[0091] The Variant and the Target species are here assumed to differ only from each other by a single polymorphic nucleotide, shown as a thick black line segment or black circle. In this example, the polymorphic nucleotide resides in the 33 and 36 regions. Here, it was assumed that regions 18 and 29 differ in sequence only at the nucleotide complementary to the polymorphic nucleotide, and that regions 19 and 30 are identical in sequence. In actuality, this does not need to be the case: for example, the complements to polymorphic nucleotide could reside in region 2 of the Probe and in region 30 of the Sink that is to say, the positions in which the Probe binds the Target/Variant need not be the same as the positions in which the Sink binds the Variant/Target. Regions 35 and 38 on the Variant and Target in
[0092] Hypothetically, it would be desirable for ΔG°.sub.rxn1 and ΔG°.sub.rxn2 to be as negative (favorable) as possible, and simultaneously ΔG°.sub.rxn3 and ΔG°.sub.rxn4 should be as positive (unfavorable) as possible. However, these values are necessarily coupled:
ΔΔG°.sub.1=ΔG°.sub.rxn3−ΔG°.sub.rxn1
ΔΔG°.sub.2=ΔG°.sub.rxn4−ΔG°.sub.rxn2
[0093] The values of ΔΔG°.sub.1 and ΔΔG°.sub.2, in turn, are influenced by the relative thermodynamics of a single-base mismatch (in general, ΔΔG°.sub.1≠ΔΔG°.sub.2). Based on experimental data and analysis, it has been determined that optimal values of ΔG°.sub.rxn1 and ΔG°.sub.rxn2 depend to some degree on ΔΔG° values.
[0094] One way to conceptualize the coupling between the different ΔG°.sub.rxn terms and their effects on the Competitive Composition performance is to consider the equilibrium for each of the Probe's and the Sink's individual reactions with the Target and the Variant. In such a simplified scenario, each reaction yield (defined as the fraction of the Target or Variant that is hybridized to the Probe or Sink at equilibrium) can be analytically computed based on the value of ΔG°.sub.rxn (
Design Principles
[0095] The values of ΔΔG°.sub.1 and ΔΔG°.sub.2 are influenced by the single-base mismatch bubbles generated between the Variant-Probe complex (V.Math.Probe) and the Target-Sink complex (T.Math.Sink), respectively. Larger values of these two terms offer greater potential enrichment, but this potential can only be tapped via proper design of Probe and Sink with optimized ΔG°.sub.rxn1 and ΔG°.sub.rxn2 values.
[0096] Referring back to
[0097] To explore these tradeoffs in realistic settings, the conditionally fluorescent X-Probe was considered as a model application for Target detection. The Binding affinity fold-change β=(f.sub.A.Math.X)/(f.sub.B+f.sub.C) represents the detectable fluorescence difference due to a small amount of the Target. Given the large number of species and reaction parameters in the Competitive Composition, analytical solution and optimization is unlikely to yield simple solutions conducive to intuitive understanding. Therefore, ordinary differential equation (ODE) simulations of the Competitive Composition system were performed in order to examine the landscape of Binding affinity fold-change due to various factors. The simulation follows the rate laws of chemical reaction and integrates the reaction process numerically.
[0098] For accuracy, modeled incidental species in the Probe and Sink components were also considered (
where R represents the Target, D represents the Variant, k+ and k− represent the forward and the reverse rate constants respectively. The names and structures of other species are illustrated in
[0099] For k.sub.1−, ΔG°.sub.rxn1 was used; for k.sub.2−, ΔG°.sub.rxn2; for k.sub.3−, ΔG°.sub.rxn3 ≡ΔG°.sub.rxn1+ΔΔG°.sub.1; for k.sub.4−, ΔG°.sub.rxn4≡ΔG°.sub.rxn2+ΔΔG°.sub.2, for k.sub.5−, ΔG°.sub.rxn5≡ΔG°.sub.rxn1+ΔG°.sub.NH; for k.sub.6−, ΔG°.sub.rxn6 ≡ΔG°.sub.rxn1+ΔΔG°.sub.1+ΔG°.sub.NH. The term ΔG°.sub.NB denotes the nonhomologous region that is missing for the incomplete QPC species of the Probe, and has value −8.46 kcal/mol. For all simulations here, ΔΔG°.sub.1=+3 kcal/mol and ΔΔG°.sub.2=+4 kcal/mol. The ODE simulation of the above reactions consists of the following rate law equations:
[0100]
[0101] There is an optimal value range for ΔG°.sub.rxn1 and ΔG°.sub.rxn2 that yields high Binding affinity fold-change (
[0102] Furthermore,
[0103] In the above simulations, ΔΔG°.sub.1 and ΔΔG°.sub.2 were assumed to be +3 and +4 kcal/mol. Through the course of our simulations and investigations, it has been determined that the optimal ΔG°.sub.rxn1 and ΔG°.sub.rxn2 ranges are relatively insensitive to parameters such as Probe concentration [FQPC], Sink concentration [P.sub.SC.sub.S], reaction time, and background fluorescence level f.sub.B. They are, however, sensitive to the stoichiometric ratios ([QP]/[FQPC]), ([P.sub.S]/[P.sub.SC.sub.S]), and ΔΔG° values, consistent with prior art on double-stranded probes.
[0104] Consequently, the following ranges of ΔG°.sub.rxn values are reasonable for this embodiment (X-Probe as Probe, ultraspecific probes as Sink) of Competitive Compositions:
−4 kcal/mol≤ΔG°.sub.rxn1+Rτ ln([QP]/[FQPC]])≤+3 kcal/mol
−7 kcal/mol≤ΔG°.sub.rxn2+Rτ ln([P.sub.S]/[P.sub.SC.sub.S])≤+1 kcal/mol (1)
where R is the ideal gas constant and τ is the temperature in Kelvin, and concentrations shown are initial concentrations before addition of sample. As can be seen, high performance is generally observed when the Sink binds more favorably to the Variant than the Probe to the Target (ΔG°.sub.rxn1<ΔG°.sub.rxn2). Competitive Compositions utilizing other Probe and Sink morphologies that result in auxiliary species release follow the same range guidelines for ΔG°.sub.rxn values. Use of Probe morphologies that do not release auxiliary species (e.g. molecular beacons, hairpin probes, and triple-stem probes instead follows:
−4 kcal/mol≤ΔG°.sub.rxn1−Rτ ln([Probe])≤+3 kcal/mol (2)
Similarly, use of Sink morphologies that do not release auxiliary species follows:
−7 kcal/mol≤ΔG°.sub.rxn2−Rτ ln([Sink])≤+1 kcal/mol (3)
[0105] The values of ΔG°.sub.rxn1 and ΔG°.sub.rxn2 for a given Probe and Sink design can be calculated using software such as NUPACK or mFold based on their sequences; such calculations are described in more detail in literature describing the component probes themselves and is considered accessible by people of ordinary skill in the art of thermodynamics-guided nucleic acid probe design. Simultaneous use of multiple Probes with different morphologies targeting the same Target species is not recommended; simultaneous use of multiple Sinks with different morphologies targeting the same Variant species is not recommended.
[0106] For example, the standard reaction free energy of the interaction between the target nucleic acid probe (Probe) and target nucleic acid T of
ΔG°.sub.rxn1=ΔG°.sub.34-19−ΔG°.sub.22-23−ΔG°.sub.20-21−ΔG°.sub.ML+(ΔG°.sub.33-18−ΔG°.sub.17-18)−ΔG°.sub.label
where ΔG°.sub.34-19 is the standard free energy of the hybridization between subsequence 34 and subsequence 19, ΔG°.sub.22-23 is the standard free energy of the hybridization between subsequence 22 and subsequence 23, ΔG°.sub.20-21 is the standard free energy of the hybridization between subsequence 20 and subsequence 21, ΔG°.sub.ML is the standard free energy of the hybridization in the multi-loop provided at the intersection of the four oligonucleotides, ΔG°.sub.33-18 is the standard free energy of the hybridization between subsequence 33 and subsequence 18, ΔG°.sub.17-18 is the standard free energy of the hybridization between subsequence 17 and subsequence 18, and ΔG°.sub.label is the standard free energy difference between the thermodynamic contribution of the label on the third oligonucleotide when it is in close proximity to the label on the fourth oligonucleotide (not shown) versus when they are delocalized.
[0107] Additionally, the standard reaction free energy of the interaction between the non-target nucleic acid probe (Sink) and non-target nucleic acid V of
ΔG°.sub.rxn2=ΔG°.sub.t-TC+ΔG°.sub.nh-PC+(ΔG°.sub.v-TC−ΔG°.sub.h-Pc)
where ΔG°.sub.t-TC is the standard free energy of the hybridization between subsequence 37 and subsequence 30, ΔG°.sub.nh-PC is the standard free energy of the hybridization between subsequence 31 and subsequence 32, ΔG°.sub.v-TC is the standard free energy of the hybridization between subsequence 36 and subsequence 29, ΔG°.sub.nh-PC is the standard free energy of the hybridization between subsequence 28 and subsequence 29.
[0108] Finally, although Signal Increase is a metric specific to conditionally fluorescent Competitive Compositions for detection of Target, other applications that utilize the enrichment capabilities of the Competitive Composition, such as in situ hybridization-based imaging or enzyme-based amplification, likely also face a tradeoff between specificity and sensitivity, so that the guidelines for ΔG°.sub.rxn1 and ΔG°.sub.rxn2 are likely to be generally suitable.
Other Applications of Competitive Compositions
[0109] Another example embodiment of Competitive Composition involves indirect linkage of the Probe species to a functionalized oligo (known as a Universal Functionalized Strand) via one or more hybridization interactions on additional domains (
[0110] Another example embodiment of Competitive Composition involves the usage of the Probe as a primer for enzymatic amplification (
Design Process
[0111] Many potential design processes can be used to generate the sequences employed in a Competitive Composition. The following provides one example.
[0112] 1) Select the Target and Variant as subsequences from a target nucleic acid. The Target and Variant must contain the polymorphic nucleotide(s) of interest, and are otherwise identical. Considerations, such as Target and Variant secondary structure, can be used to inform Target and Variant sequence selection.
[0113] (2) Determine operation conditions, including temperature, buffer salinity, crowding/denaturing agents, reaction time, and readout mechanism.
[0114] (3) Select morphologies of the Probe and the Sink. Considerations, such as cost and complexity of the components, can be used to guide/inform morphology selection.
[0115] (4) Calculate or estimate ΔΔG°.sub.1 and ΔΔG°.sub.2 based on the Target and Variant sequences at desired operation conditions. Thermodynamic values for DNA-DNA and RNA-RNA mismatch bubbles for certain operation conditions are available in literature; for other nucleic acids or conditions, ΔΔG° values can only be coarsely estimated.
[0116] (5) Determine optimal values of ΔG°.sub.rxn1 and ΔG°.sub.rxn2 via ordinary differential equation simulations, such as described in this document. Binding affinity fold-change (or other relevant metric) will be calculated for many different ΔG°.sub.rxn values based on ΔΔG° values, predetermined background signal, Target and Variant concentrations, and Probe and Sink concentrations.
[0117] (6) Design Target-specific Probe based on selected morphology and selected ΔG°.sub.rxn1 value, with iterative fine-tuning of sequence as necessary. Other considerations such as oligonucleotide lengths, functionalizations utilized, etc. can be used for further guide and inform Probe sequence selection.
[0118] (7) Design Variant-specific Sink based on selected morphology and selected ΔG°.sub.rxn2 value, with iterative fine-tuning of sequence as necessary. Other considerations such as oligonucleotide lengths, functionalizations utilized, etc. can be used for further guide and inform Sink sequence selection.
Examples
Experimental Results on Conditionally Fluorescent Competitive Compositions
[0119] To experimentally validate the ability for Competitive Compositions to enrich Target over Variant in binding to the probe, experiments were designed and performed on a conditionally fluorescent version of the Probe (
[0120] Referring now to
[0121]
[0122] A different metric to utilize is “Binding affinity fold-change β”, defined as (f.sub.A.Math.X)/(f.sub.B+f.sub.C). Binding affinity fold-change is likely the most reproducible and robust metric because the background fluorescence level f.sub.B may vary due to autofluorescence from different cuvettes, or differences in sample holder positions, or other changes. A lower bound for the enrichment factor (X/Y) can be calculated as the Binding affinity fold-change.
[0123] Similar experiments to
TABLE-US-00001 TABLE 1 Sequences for the Probes, Sinks, Targets, and Variants used in the Experiments of FIG. 9A-9D. SEQ ID Allele dG°rxn1 dG°rxn2 Species NO. Sequence SMAD 7-C −1.38 −4.33 P 5 AAGGACGAGCAAATGTACCTG CACTCATCCAAAAGAGGAAA C 6 GGGTCCTGTTTCCTCTTTTGGATGAGTG GTCTACTATCCACGATTTAAC Ps 7 CGACTCTCATCCAAAAGAGGAA Cs 8 GGGTCCTATTTCCTCTTTTGGATGAGAGTCG SMAD7-T −0.90 −5.07 P 9 AAGGACGAGCAAATGTACCTG CACTCATCCAAAAGAGGAA C 10 GGGTCCTATTTCCTCTTTTGGATGAGTG GTCTACTATCCACGATTTAAC Ps 11 ACACACTCATCCAAAAGAGGAAA Cs 12 GGGTCCTGTTTCCTCTTTTGGATGAGTGTGT BRAF-D594G −0.66 −2.35 T 13 ATAGGTGGTTTTGGTCTAGCTACAGTGAAA (c.1781A>G) V 14 ATAGGTGATTTTGGTCTAGCTACAGTGAAA P 15 AAGGACGAGCAAATGTACCTG CAAGGTGGTTTTGGTCTAGC C 16 TTCACTGTAGCTAGACCAAAACCACCTTG GTCTACTATCCACGATTTAAC Ps 17 TGTTAATAAGGTGATTTTGGTCTAGC Cs 18 TCACTGTAGCTAGACCAAAATCACCTTATTAACA BRAF-V600E −1.59 −4.29 T 19 ATAGGTGATTTTGGTCTAGCTACAGAGAAA (c.1799T>A) V 20 ATAGGTGATTTTGGTCTAGCTACAGTGAAA P 21 AAGGACGAGCAAATGTACCTG CAAGGTGATTTTGGTCTAG C 22 TCTCTGTAGCTAGACCAAAATCACCTTG GTCTACTATCCACGATTTAAC Ps 23 CGCAGGTGATTTTGGTCTAGC Cs 24 TCACTGTAGCTAGACCAAAATCACCTGCG EGFR-G719A 0.35 −5.21 T 25 TTCAAAAAGATCAAAGTGCTGGCCTCCGGT (c.2156G>C) V 26 TTCAAAAAGATCAAAGTGCTGGGCTCCGGT P 27 AAGGACGAGCAAATGTACCTG CACAAAAAGATCAAAGTGCTGG C 28 CGGAGGCCAGCACTTTGATCTTTTTGTG GTCTACTATCCACGATTTAAC Ps 29 AGGCAAAAAGATCAAAGTGCTGG Cs 30 CGGAGCCCAGCACTTTGATCTTTTTGCCT EGFR-S7681 −0.72 −5.18 T 31 GCCTACGTGATGGCCATCGTGGACAACCCC (c.2303G>T) V 32 GCCTACGTGATGGCCAGCGTGGACAACCCC P 33 AAGGACGAGCAAATGTACCTG CACTACGTGATGGCCATCGT C 34 GGTTGTCCACGATGGCCATCACGTAGTG GTCTACTATCCACGATTTAAC Ps 35 AGTTCTACGTGATGGCCAGCGTG Cs 36 GGTTGTCCACGCTGGCCATCACGTAGAACT EGFR-T790M −0.10 −2.75 T 37 GTGCAGCTCATCATGCAGCTCATGCCCTTC (c.2369C>T) V 38 GTGCAGCTCATCACGCAGCTCATGCCCTTC P 39 AAGGACGAGCAAATGTACCTG CAGCAGCTCATCATGCAGCTC C 40 AGGGCATGAGCTGCATGATGAGCTGCTG GTCTACTATCCACGATTTAAC Ps 41 TGTTAATAGCAGCTCATCACGCAGCTC Cs 42 AGGGCATGAGCTGCGTGATGAGCTGCTATTAACA EGFR-L858R −1.28 −2.69 T 43 ATGTCAAGATCACAGATTTTGGGCGGGCCA (c.2573T>G) V 44 ATGTCAAGATCACAGATTTTGGGCTGGCCA P 45 AAGGACGAGCAAATGTACCTG CAGTCAAGATCACAGATTTTGG C 46 GCCCGCCCAAAATCTGTGATCTTGACTG GTCTACTATCCACGATTTAAC Ps 47 TGTTAATAGTCAAGATCACAGATTTTGG Cs 48 GCCAGCCCAAAATCTGTGATCTTGACTATTAACA EGFR-L861Q −0.39 −4.45 T 49 TGGCCAAACAGCTGGGTGCGGAAGAGAAAG (c.2582T>A) V 50 TGGCCAAACTGCTGGGTGCGGAAGAGAAAG P 51 AAGGACGAGCAAATGTACCTG CAGCCAAACAGCTGGGTGCG C 52 TTTCTCTTCCGCACCCAGCTGTTTGGCTG GTCTACTATCCACGATTTAAC Ps 53 TAGTTGCCAAACTGCTGGGTGCG Cs 54 TTCTCTTCCGCACCCAGCAGTTTGGCAACTA ERBB2-S310F −0.41 −3.90 T 55 ACTACCTTTCTACGGACGTGGGATTCTGCA (c.929C>T) V 56 ACTACCTTTCTACGGACGTGGGATCCTGCA P 57 AAGGACGAGCAAATGTACCTG CATACCTTTCTACGGACGTG C 58 CAGAATCCCACGTCCGTAGAAAGGTATG GTCTACTATCCACGATTTAAC Ps 59 TGTTAATATACCTTTCTACGGACGTG Cs 60 CAGGATCCCACGTCCGTAGAAAGGTATATTAACA ERBB2-L755S −1.44 −4.49 T 61 TTCCAGTGGCCATCAAAGTGTCGAGGGAAA (c.2264T>C) V 62 TTCCAGTGGCCATCAAAGTGTTGAGGGAAA P 63 AAGGACGAGCAAATGTACCTG CACCAGTGGCCATCAAAGTG C 64 TCCCTCGACACTTTGATGGCCACTGGTG GTCTACTATCCACGATTTAAC Ps 65 GTTAATACCAGTGGCCATCAAAGTG Cs 66 TCCCTCAACACTTTGATGGCCACTGGTATTAAC ERBB2-V842I −0.84 −4.92 T 67 GGATGTGCGGCTCATACACAGGGACTTGGC (c.2524G>A) V 68 GGATGTGCGGCTCGTACACAGGGACTTGGC P 69 AAGGACGAGCAAATGTACCTG CAATGTGCGGCTCATACACA C 70 CAAGTCCCTGTGTATGAGCCGCACATTG GTCTACTATCCACGATTTAAC Ps 71 GTTAATAATGTGCGGCTCGTACACA Cs 72 CAAGTCCCTGTGTACGAGCCGCACATTATTAAC KRAS-G12A −1.99 −3.40 T 73 CTTGTGGTAGTTGGAGCTGCTGGC (c.35G>C) V 74 CTTGTGGTAGTTGGAGCTGGTGGC P 75 AAGGACGAGCAAATGTACCTG CAACTTGTGGTAGTTGGAG C 76 GCCAGCAGCTCCAACTACCACAAGTTG GTCTACTATCCACGATTTAAC Ps 77 CCGCTGTGGTAGTTGGA Cs 78 CACCAGCTCCAACTACCACAGCGC KRAS-G12C 1.28 −3.40 T 79 CTTGTGGTAGTTGGAGCTTGTGGC (c.34G>T) V 80 CTTGTGGTAGTTGGAGCTGGTGGC P 81 AAGGACGAGCAAATGTACCTG CAACTTGTGGTAGTTGGAGC C 82 GCCACAAGCTCCAACTACCACAAGTTG GTCTACTATCCACGATTTAAC Ps 83 CCGCTGTGGTAGTTGGA Cs 84 CACCAGCTCCAACTACCACAGCGC KRAS-G12D −0.66 −3.77 T 85 CTTGTGGTAGTTGGAGCTGATGGC (c.35G>A) V 86 CTTGTGGTAGTTGGAGCTGGTGGC P 87 AAGGACGAGCAAATGTACCTG CAACTTGTGGTAGTTGGAG C 88 GCCATCAGCTCCAACTACCACAAGTTG GTCTACTATCCACGATTTAAC Ps 89 GCATCTGTGGTAGTTGGA Cs 90 CACCAGCTCCAACTACCACAGATGC KRAS-G12R 0.26 −3.40 T 91 CTTGTGGTAGTTGGAGCTCGTGGC (c.34G>C) V 92 CTTGTGGTAGTTGGAGCTGGTGGC P 93 AAGGACGAGCAAATGTACCTG CAACTTGTGGTAGTTGGAGC C 94 GCCACGAGCTCCAACTACCACAAGTTG GTCTACTATCCACGATTTAAC Ps 95 CCGCTGTGGTAGTTGGA Cs 96 CACCAGCTCCAACTACCACAGCGC KRAS-G12S −0.34 −3.40 T 97 CTTGTGGTAGTTGGAGCTAGTGGC (c.34G>A) V 98 CTTGTGGTAGTTGGAGCTGGTGGC P 99 AAGGACGAGCAAATGTACCTG CAACTTGTGGTAGTTGGAG C 100 GCCACTAGCTCCAACTACCACAAGTTG GTCTACTATCCACGATTTAAC Ps 101 CCGCTGTGGTAGTTGGA Cs 102 CACCAGCTCCAACTACCACAGCGC KRAS-G12V −0.92 −3.40 T 103 CTTGTGGTAGTTGGAGCTGTTGGC (c.35G>T) V 104 CTTGTGGTAGTTGGAGCTGGTGGC P 105 AAGGACGAGCAAATGTACCTG CAACTTGTGGTAGTTGGAG C 106 GCCAACAGCTCCAACTACCACAAGTTG GTCTACTATCCACGATTTAAC Ps 107 CCGCTGTGGTAGTTGGA Cs 108 CACCAGCTCCAACTACCACAGCGC KRAS-G13C −0.92 −2.85 T 109 CTTGTGGTAGTTGGAGCTGGTTGC (c.37G>T) V 110 CTTGTGGTAGTTGGAGCTGGTGGC P 111 AAGGACGAGCAAATGTACCTG CAACTTGTGGTAGTTGGAG C 112 GCAACCAGCTCCAACTACCACAAGTTG GTCTACTATCCACGATTTAAC Ps 113 CAGGCTGTGGTAGTTGGA Cs 114 CACCAGCTCCAACTACCACAGCCTG KRAS-G13D −0.69 −6.06 T 115 CTTGTGGTAGTTGGAGCTGGTGACGTAGGC (c.38G>A) V 116 CTTGTGGTAGTTGGAGCTGGTGGCGTAGGC P 117 AAGGACGAGCAAATGTACCTG CATGTGGTAGTTGGAGCTGG C 118 CTACGTCACCAGCTCCAACTACCACATG GTCTACTATCCACGATTTAAC Ps 119 TTAATATGTGGTAGTTGGAGCTGGT Cs 120 CTACGCCACCAGCTCCAACTACCACATATTAA KRAS-G13V −0.69 −6.32 T 121 CTTGTGGTAGTTGGAGCTGGTGTCGTAGGC (c.38G>T) V 122 CTTGTGGTAGTTGGAGCTGGTGGCGTAGGC P 123 AAGGACGAGCAAATGTACCTG CATGTGGTAGTTGGAGCTGG C 124 CTACGACACCAGCTCCAACTACCACATG GTCTACTATCCACGATTTAAC Ps 125 AGGTGTGGTAGTTGGAGCTGGT Cs 126 CTACGCCACCAGCTCCAACTACCACACCT KRAS-Q61H −0.64 −3.29 T 127 GCAGGTCACGAGGAGTACAGTGCAATGAGG (c.183A>C) V 128 GCAGGTCAAGAGGAGTACAGTGCAATGAGG P 129 AAGGACGAGCAAATGTACCTG CAAGGTCACGAGGAGTACAG C 130 TCATTGCACTGTACTCCTCGTGACCTTG GTCTACTATCCACGATTTAAC Ps 131 TGTTAATAAGGTCAAGAGGAGTACAG Cs 132 TCATTGCACTGTACTCCTCTTGACCTTATTAACA MAP2K1-K57N −0.32 −5.87 T 133 ACCCAGAATCAGAAGGTGGGAGAACTGAAG (c.171G>T) V 134 ACCCAGAAGCAGAAGGTGGGAGAACTGAAG P 135 AAGGACGAGCAAATGTACCTG CACCAGAATCAGAAGGTGGG C 136 TTCAGTTCTCCCACCTTCTGATTCTGGTG GTCTACTATCCACGATTTAAC Ps 137 AGGCCAGAAGCAGAAGGTGGG Cs 138 TCAGTTCTCCCACCTTCTGCTTCTGGCCT NRAS-G12C 0.20 −5.30 T 139 GTGGTTGGAGCATGTGGTGTTGGGAAAAGC (c.34G>T) V 140 GTGGTTGGAGCAGGTGGTGTTGGGAAAAGC P 141 AAGGACGAGCAAATGTACCTG CAGGTTGGAGCATGTGGTGTT C 142 CTTTTCCCAACACCACATGCTCCAACCTG GTCTACTATCCACGATTTAAC Ps 143 AGGGGTTGGAGCAGGTGGTGT Cs 144 TTTTCCCAACACCACCTGCTCCAACCCCT NRAS-G12D 0.20 −5.30 T 145 GTGGTTGGAGCAGATGGTGTTGGGAAAAGC (c.35G>A) V 146 GTGGTTGGAGCAGGTGGTGTTGGGAAAAGC P 147 AAGGACGAGCAAATGTACCTG CAGGTTGGAGCAGATGGTGTT C 148 CTTTTCCCAACACCATCTGCTCCAACCTG GTCTACTATCCACGATTTAAC Ps 149 AGGGGTTGGAGCAGGTGGTGT Cs 150 TTTTCCCAACACCACCTGCTCCAACCCCT NRAS-G12S 0.55 −5.24 T 151 TACAAACTGGTGGTGGTTGGAGCAAGTGGT (c.34G>A) V 152 TACAAACTGGTGGTGGTTGGAGCAGGTGGT P 153 AAGGACGAGCAAATGTACCTG CTCAAACTGGTGGTGGTTGGA C 154 CACTTGCTCCAACCACCACCAGTTTGAG GTCTACTATCCACGATTTAAC Ps 155 CGATCAAACTGGTGGTGGTTGGA Cs 156 CACCTGCTCCAACCACCACCAGTTTGATCG NRAS-G13D 0.20 −5.30 T 157 GTGGTTGGAGCAGGTGATGTTGGGAAAAGC (c.38G>A) V 158 GTGGTTGGAGCAGGTGGTGTTGGGAAAAGC P 159 AAGGACGAGCAAATGTACCTG CAGGTTGGAGCAGGTGATGTT C 160 CTTTTCCCAACATCACCTGCTCCAACCTG GTCTACTATCCACGATTTAAC Ps 161 AGGGGTTGGAGCAGGTGGTGT Cs 162 TTTTCCCAACACCACCTGCTCCAACCCCT NRAS-Q61H −0.80 −3.40 T 163 ATACTGGATACAGCTGGACATGAAGAGTAC (c.183A>T) V 164 ATACTGGATACAGCTGGACAAGAAGAGTAC P 165 AAGGACGAGCAAATGTACCTG CAACTGGATACAGCTGGAC C 166 ACTCTTCATGTCCAGCTGTATCCAGTTG GTCTACTATCCACGATTTAAC Ps 167 TGTTAATAACTGGATACAGCTGGAC Cs 168 ACTCTTCTTGTCCAGCTGTATCCAGTTATTAACA NRAS-Q61K −0.28 −3.40 T 169 ATACTGGATACAGCTGGAAAAGAAGAGTAC (c.181C>A) V 170 ATACTGGATACAGCTGGACAAGAAGAGTAC P 171 AAGGACGAGCAAATGTACCTG CAACTGGATACAGCTGGAA C 172 ACTCTTCTTTTCCAGCTGTATCCAGTTG GTCTACTATCCACGATTTAAC Ps 173 TGTTAATAACTGGATACAGCTGGAC Cs 174 ACTCTTCTTGTCCAGCTGTATCCAGTTATTAACA NRAS-Q61L −0.89 −4.12 T 175 GGACATACTGGATACAGCTGGACTAGAAGA (c.182A>T) V 176 GGACATACTGGATACAGCTGGACAAGAAGA P 177 AAGGACGAGCAAATGTACCTG CAACATACTGGATACAGCT C 178 TTCTAGTCCAGCTGTATCCAGTATGTTG GTCTACTATCCACGATTTAAC Ps 179 GTTAATAACATACTGGATACAGCTG Cs 180 TTCTTGTCCAGCTGTATCCAGTATGTTATTAAC NRAS-Q61R −0.20 −1.98 T 181 ATACTGGATACAGCTGGACGAGAAGAGTAC (c.182A>G) V 182 ATACTGGATACAGCTGGACAAGAAGAGTAC P 183 AAGGACGAGCAAATGTACCTG CAACTGGATACAGCTGGACG C 184 TACTCTTCTCGTCCAGCTGTATCCAGTTG GTCTACTATCCACGATTTAAC Ps 185 GTGTTAATAACTGGATACAGCTGGAC Cs 186 ACTCTTCTTGTCCAGCTGTATCCAGTTATTAACAC PIK3CA-E542K −0.52 −4.79 T 187 CTCTCTAAAATCACTGAGCAGGAGAAAGAT (c.1624G>A) V 188 CTCTCTGAAATCACTGAGCAGGAGAAAGAT P 189 AAGGACGAGCAAATGTACCTG CACTCTAAAATCACTGAGCA C 190 TCTTTCTCCTGCTCAGTGATTTTAGAGTG GTCTACTATCCACGATTTAAC Ps 191 AGGCTCTGAAATCACTGAGCA Cs 192 CTTTCTCCTGCTCAGTGATTTCAGAGCCT PIK3CA-E545K −0.36 −5.25 T 193 AGATCCTCTCTCTGAAATCACTAAGCAGGA (c.1633G>A) V 194 AGATCCTCTCTCTGAAATCACTGAGCAGGA P 195 AAGGACGAGCAAATGTACCTG CAATCCTCTCTCTGAAATCAC C 196 CCTGCTTAGTGATTTCAGAGAGAGGATTG GTCTACTATCCACGATTTAAC Ps 197 TTAATAATCCTCTCTCTGAAATCAC Cs 198 CTGCTCAGTGATTTCAGAGAGAGGATTATTAA PIK3CA-H1047L −0.81 −3.47 T 199 TGATGCACTTCATGGTGGCTGGACAACAAA (c.3140A>T) V 200 TGATGCACATCATGGTGGCTGGACAACAAA P 201 AAGGACGAGCAAATGTACCTG CAATGCACTTCATGGTGGCT C 202 TGTTGTCCAGCCACCATGAAGTGCATTG GTCTACTATCCACGATTTAAC Ps 203 TGTTAATAATGCACATCATGGTGGCT Cs 204 TGTTGTCCAGCCACCATGATGTGCATTATTAACA PIK3CA-H1047R −0.81 −2.05 T 205 TGATGCACGTCATGGTGGCTGGACAACAAA (c.3140A>G) V 206 TGATGCACATCATGGTGGCTGGACAACAAA P 207 AAGGACGAGCAAATGTACCTG CAATGCACGTCATGGTGGCT C 208 TGTTGTCCAGCCACCATGACGTGCATTG GTCTACTATCCACGATTTAAC Ps 209 GTGTTAATAATGCACATCATGGTGGCT Cs 210 TGTTGTCCAGCCACCATGATGTGCATTATTAACAC STK11-Q37* 1.02 −3.70 T 211 ATCGACTCCACCGAGGTCATCTACTAGCCG (c.109C>T) V 212 ATCGACTCCACCGAGGTCATCTACCAGCCG P 213 AAGGACGAGCAAATGTACCTG CACGACTCCACCGAGGTCAT C 214 GCTGGTAGATGACCTCGGTGGAGTCGTG GTCTACTATCCACGATTTAAC Ps 215 CACCACGACTCCACCGAGGTCAT Cs 216 GCTGGTAGATGACCTCGGTGGAGTCGTGGTG STK11-P281L 0.34 −3.56 T 217 ATCCCGGGCGACTGTGGCCCCCTGCTCTCT (c.842C>T) V 218 ATCCCGGGCGACTGTGGCCCCCCGCTCTCT P 219 AAGGACGAGCAAATGTACCTG CACCCGGGCGACTGTGGCCCC C 220 AGAGCAGGGGGCCACAGTCGCCCGGGTG GTCTACTATCCACGATTTAAC Ps 221 TGTTAATACCCGGGCGACTGTGGCCCC Cs 222 AGAGCGGGGGGCCACAGTCGCCCGGGTATTAACA STK11-F354L 0.33 −3.75 T 223 AGGACCTCTTGGACATCGAGGATGACATCA (c.1062C>G) V 224 AGGACCTCTTCGACATCGAGGATGACATCA P 225 AAGGACGAGCAAATGTACCTG CAGACCTCTTGGACATCGAG C 226 ATGTCATCCTCGATGTCCAAGAGGTCTG GTCTACTATCCACGATTTAAC Ps 227 GTTAATAGACCTCTTCGACATCGAG Cs 228 ATGTCATCCTCGATGTCGAAGAGGTCTATTAAC TP53-R175H 0.00 −4.23 T 229 GTTGTGAGGCACTGCCCCCACCATGAGCGC (c.524G>A) V 230 GTTGTGAGGCGCTGCCCCCACCATGAGCGC P 231 AAGGACGAGCAAATGTACCTG CATGTGAGGCACTGCCCCCAC C 232 GCTCATGGTGGGGGCAGTGCCTCACATG GTCTACTATCCACGATTTAAC Ps 233 GTCGAGGCGCTGCCCCCACCATG Cs 234 AGCGCTCATGGTGGGGGCAGCGCCTCGAC TP53-R213* −1.46 −3.54 T 235 ACTTTTTGACATAGTGTGGTGGTGCCCTAT (c.637C>T) V 236 ACTTTTCGACATAGTGTGGTGGTGCCCTAT P 237 AAGGACGAGCAAATGTACCTG CATTTTTGACATAGTGTGGTG C 238 AGGGCACCACCACACTATGTCAAAAATG GTCTACTATCCACGATTTAAC Ps 239 AAGACAATTTTCGACATAGTGTGGTG Cs 240 AGGGCACCACCACACTATGTCGAAAATTGTCTT TP53-Y220C 0.08 −2.92 T 241 CGACATAGTGTGGTGGTGCCCTGTGAGCCG (c.659A>G) V 242 CGACATAGTGTGGTGGTGCCCTATGAGCCG P 243 AAGGACGAGCAAATGTACCTG CAACATAGTGTGGTGGTGCCC C 244 GCTCACAGGGCACCACCACACTATGTTG GTCTACTATCCACGATTTAAC Ps 245 TGTTAATAACATAGTGTGGTGGTGCC Cs 246 GCTCATAGGGCACCACCACACTATGTTATTAACA TP53-R248Q −0.38 −6.06 T 247 TTCCTGCATGGGCGGCATGAACCAGAGGCC (c.743G>A) V 248 TTCCTGCATGGGCGGCATGAACCGGAGGCC P 249 AAGGACGAGCAAATGTACCTG CACCTGCATGGGCGGCATGA C 250 CCTCTGGTTCATGCCGCCCATGCAGGTG GTCTACTATCCACGATTTAAC Ps 251 GCCCTGCATGGGCGGCATGAAC Cs 252 CCTCCGGTTCATGCCGCCCATGCAGGGC TP53-R248W −0.26 −2.91 T 253 ATGAACTGGAGGCCCATCCTCACCATCATC (c.742C>T) V 254 ATGAACCGGAGGCCCATCCTCACCATCATC P 255 AAGGACGAGCAAATGTACCTG CAGAACTGGAGGCCCATCCT C 256 TGATGGTGAGGATGGGCCTCCAGTTCTG GTCTACTATCCACGATTTAAC Ps 257 TGTTAATAGAACCGGAGGCCCATCCT Cs 258 TGATGGTGAGGATGGGCCTCCGGTTCTATTAACA TP53-R273C 0.18 −3.18 T 259 ACGGAACAGCTTTGAGGTGTGTGTTTGTGC (c.817C>T) V 260 ACGGAACAGCTTTGAGGTGCGTGTTTGTGC P 261 AAGGACGAGCAAATGTACCTG CAGGAACAGCTTTGAGGTGT C 262 ACAAACACACACCTCAAAGCTGTTCCTG GTCTACTATCCACGATTTAAC Ps 263 TGTTAATAGGAACAGCTTTGAGGTGC Cs 264 ACAAACACGCACCTCAAAGCTGTTCCTATTAACA TP53-R273H −1.24 −5.54 T 265 AGGTGCATGTTTGTGCCTGTCCTGGGAGAG (c.818G>A) V 266 AGGTGCGTGTTTGTGCCTGTCCTGGGAGAG P 267 AAGGACGAGCAAATGTACCTG CAGTGCATGTTTGTGCCTGT C 268 CTCCCAGGACAGGCACAAACATGCACTG GTCTACTATCCACGATTTAAC Ps 269 AGTTGTGCGTGTTTGTGCCTGTC Cs 270 CTCCCAGGACAGGCACAAACACGCACAACT TP53-R282W 0.28 −3.81 T 271 GGGAGAGACTGGCGCACAGAGGAAGAGAAT (c.844C>T) V 272 GGGAGAGACCGGCGCACAGAGGAAGAGAAT P 273 AAGGACGAGCAAATGTACCTG CAGAGAGACTGGCGCACAGA C 274 TCTCTTCCTCTGTGCGCCAGTCTCTCTG GTCTACTATCCACGATTTAAC Ps 275 GTTAATAGAGAGACCGGCGCACAGA Cs 276 TCTCTTCCTCTGTGCGCCGGTCTCTCTATTAAC
TABLE-US-00002 TABLE 2 Sequences used for the Third Oligonucleotide (F) and Fourth Oligonucleotide (Q) used with the Probe Sequences of Table 1. SEQ ID Species NO. Sequence F 1 GTTAAATCGTGGATAGTAGAC TTCGCAC/3Rox N/ Q 2 /5IAbRQ/GTGCGAA CAGGTACATTTGCTCGTCCTT
TABLE-US-00003 TABLE 3 Sequences non-allele specific primers at SMAD7 gene locus. SEQ ID Primer NO. Sequence Forward 3 CCATGCTCACAGCCTCATC Primer Reverse 4 TGTTTCCTGAGGAGTCTGAGG Primer
[0124] The results are summarized in
[0125] The primary reason for the improvement of the Competitive Composition over a good Target-specific Probe alone is that the Competitive Composition captures the enrichment power of both ΔΔG°.sub.1 and ΔΔG°.sub.2, whereas the Target-specific Probe alone captures only ΔΔG°.sub.1.
[0126]
[0127] Therefore, the present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. While numerous changes may be made by those skilled in the art, such changes are encompassed within the spirit of this invention as illustrated, in part, by the appended claims.